Bortezomib

Bortezomib is l-Phenylalaninamide substituted at the amide nitrogen by a 1-(dihydroxyboranyl)-3-methylbutyl group and at N(alpha) by a pyrazin-2-ylcarbonyl group. It is a dipeptidyl boronic acid that reversibly inhibits the 26S proteasome. Among its listed roles, it functions as a antineoplastic agent, a proteasome inhibitor, a protease inhibitor and an antiprotozoal drug. It is an amino acid amide, a member of pyrazines and a L-phenylalanine derivative. Functionally, it is related to boronic acid. It is grouped under the following drug class(es): Antineoplastic agents and Proteasome inhibitors. Its therapeutic use is listed as anti-cancer agents and antineoplastics. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Velcade, radiciol and bortezomibum. Its PubChem CID is 387447.

CAS No 179324-69-7
Molecular Formula C19H25BN4O4
Molecular Weight 384.2 g/mol
Synonyms [(1R)-3-methyl-1-[[(2S)-3-phenyl-2-(pyrazine-2-carbonylamino)propanoyl]amino]butyl]boronic acid

Frequently Asked Questions